Aeterna Zentaris Inc. (AEZS): Earnings News

AEZS – Reports Q2 loss of $0.18 per share.


Key Facts Surrounding This News Item


  • AEZS had a POWR Rating of F (Strong Sell) coming into today.
  • AEZS was -4.81% below its 10-Day Moving Average coming into today.
  • AEZS was -4.96% below its 20-Day Moving Average coming into today.
  • AEZS was 31.95% above its 50-Day Moving Average coming into today.
  • AEZS was 3.62% above its 100-Day Moving Average coming into today.
  • AEZS was -28.54% below its 200-Day Moving Average coming into today.
  • AEZS had returned -50.00% year-to-date leading up to today’s news, versus a +11.63% return from the benchmark S&P 500 during the same period.

More Info About Aeterna Zentaris Inc. (AEZS)


Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company was founded in 1991 and is based in Summerville, South Carolina. View our full AEZS ticker page with ratings, news, and more.

AEZS at a Glance

AEZS Current POWR Rating™
Overall POWR Rating™
AEZS Current Price $1.84 2.13%
More AEZS Ratings, Data, and News

AEZS Price Reaction

The day of this event (Aug. 10, 2017)
AEZS Closing Price$1.73 3.89%
AEZS Volume462,800
49.28% from avg
Leading up to this event
AEZS 1-mo return74.76%
After this event
AEZS 1-day return11.76%
AEZS 3-day return13.04%
AEZS 5-day return3.74%

AEZS Price Chart



More Aeterna Zentaris Inc. (AEZS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AEZS News
Page generated in 0.943 seconds.